{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:38:34Z","timestamp":1784039914481,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with type 2 diabetes mellitus (T2DM) have an elevated risk of colorectal cancer. SGLT-2 inhibitors and GLP-1 receptor agonists have demonstrated potential anticancer properties through distinct mechanisms. However, the association of combination therapy with colon cancer risk remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a target trial emulation using the TriNetX Global Collaborative Network (2017\u20132025). Adults with T2DM and a history of polypectomy receiving dual therapy (SGLT-2 inhibitor plus GLP-1 receptor agonist) were compared with SGLT-2 inhibitor monotherapy using 1:1 propensity score matching without replacement. A new-user design and 180-day landmark analysis were employed to address immortal time bias. The primary outcome was incident colon cancer. Secondary outcomes included colectomy, other gastrointestinal cancers, cardiovascular events, renal outcomes, and all-cause mortality. Bonferroni correction was applied for multiple secondary comparisons (\u03b1\u2009=\u20090.05\/11\u2009=\u20090.0045).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After propensity score matching, 28,934 patients were included in each group. Dual therapy was associated with a lower risk of colon cancer compared with SGLT-2 inhibitor alone (HR\u00a00.786, 95%\u00a0CI\u00a00.671\u20130.919;\u00a0P\u2009=\u20090.003), representing a 21% relative risk reduction (NNT\u2009=\u2009490 over 5\u00a0years). Significant reductions were also observed in colectomy (HR\u00a00.456), other gastrointestinal cancers (HR\u00a00.690), end-stage renal disease (HR\u00a00.808), major adverse kidney events (HR\u00a00.710), and all-cause mortality (HR\u00a00.658). Negative control outcomes showed no meaningful differences, supporting study validity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In post-polypectomy T2DM patients, dual therapy was associated with a 21% lower risk of colon cancer versus SGLT-2 inhibitor monotherapy. Co-primary analysis demonstrated this association also persisted when comparing dual therapy against GLP-1 receptor agonist monotherapy alone (HR\u00a00.871;\u00a0P\u2009=\u20090.041), indicating additive chemopreventive effects of the combination warranting prospective investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-026-02151-x","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T08:25:44Z","timestamp":1774772744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of dual SGLT-2 inhibitor and GLP-1 receptor agonist therapy with colon cancer risk in post-polypectomy patients with diabetes: a target trial emulation"],"prefix":"10.1186","volume":"18","author":[{"given":"Chih-Hsuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Huang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Hsun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"key":"2151_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2151_CR2","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674\u201385.","journal-title":"Diabetes Care"},{"key":"2151_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1677\/ERC-09-0087","volume":"16","author":"P Vigneri","year":"2009","unstructured":"Vigneri P, et al. Diabetes and cancer. Endocr Relat Cancer. 2009;16:1103\u201323.","journal-title":"Endocr Relat Cancer"},{"key":"2151_CR4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrc2536","volume":"8","author":"M Pollak","year":"2008","unstructured":"Pollak M. Insulin and IGF signalling in neoplasia. Nat Rev Cancer. 2008;8:915\u201328.","journal-title":"Nat Rev Cancer"},{"key":"2151_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/dmrr.912","volume":"25","author":"D Weinstein","year":"2009","unstructured":"Weinstein D, et al. Insulin analogues display IGF-I-like activities in cultured cancer cells. Diabetes Metab Res Rev. 2009;25:41\u20139.","journal-title":"Diabetes Metab Res Rev"},{"key":"2151_CR6","doi-asserted-by":"publisher","first-page":"1369352","DOI":"10.3389\/fphar.2024.1369352","volume":"15","author":"M Sun","year":"2024","unstructured":"Sun M, et al. Unveiling the anticancer effects of SGLT-2i. Front Pharmacol. 2024;15:1369352.","journal-title":"Front Pharmacol"},{"key":"2151_CR7","doi-asserted-by":"crossref","unstructured":"Nakhaei A, et al. SGLT-2 inhibitors beyond diabetes: a new frontier in cancer treatment. Diabetes Res Clin Pract. 2025; 112925.","DOI":"10.1016\/j.diabres.2025.112925"},{"key":"2151_CR8","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","volume":"5","author":"LA Villani","year":"2016","unstructured":"Villani LA, et al. Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I. Mol Metab. 2016;5:1048\u201356.","journal-title":"Mol Metab"},{"key":"2151_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/35094067","volume":"1","author":"R Fodde","year":"2001","unstructured":"Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in CRC. Nat Rev Cancer. 2001;1:55\u201367.","journal-title":"Nat Rev Cancer"},{"key":"2151_CR10","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","volume":"60","author":"H Tang","year":"2017","unstructured":"Tang H, et al. SGLT2 inhibitors and risk of cancer in T2DM: systematic review and meta-analysis. Diabetologia. 2017;60:1862\u201372.","journal-title":"Diabetologia"},{"key":"2151_CR11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/jgh.16498","volume":"39","author":"CH Chiang","year":"2024","unstructured":"Chiang CH, et al. SGLT-2 inhibitors and outcome of patients with DM and CRC. J Gastroenterol Hepatol. 2024;39:902\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"2151_CR12","first-page":"321","volume":"68","author":"JY Yang","year":"2025","unstructured":"Yang JY, et al. Colorectal cancer and SGLT-2 inhibitor use. Diabetologia. 2025;68:321.","journal-title":"Diabetologia"},{"key":"2151_CR13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2337\/dc25-1869","volume":"48","author":"JY Wang","year":"2025","unstructured":"Wang JY, et al. SGLT-2 inhibitors and colorectal cancer risk. Diabetes Care. 2025;48:180\u20138.","journal-title":"Diabetes Care"},{"key":"2151_CR14","unstructured":"Lee J, et al. SGLT-2 inhibitors and colorectal cancer risk: a population-based cohort study. J Clin Endocrinol Metab. 2024 [in press]."},{"key":"2151_CR15","volume":"6","author":"JH Kim","year":"2023","unstructured":"Kim JH, et al. Sodium-glucose cotransporter 2 inhibitors and cancer incidence. JAMA Netw Open. 2023;6:e2314453.","journal-title":"JAMA Netw Open"},{"key":"2151_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24:15\u201330.","journal-title":"Cell Metab"},{"key":"2151_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320","volume":"182","author":"G Bendotti","year":"2022","unstructured":"Bendotti G, et al. Anti-inflammatory and immunological properties of GLP-1 RAs. Pharmacol Res. 2022;182:106320.","journal-title":"Pharmacol Res"},{"key":"2151_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, et al. GLP-1 receptor agonists and colorectal cancer risk. JAMA Oncol. 2024;10:256\u20138.","journal-title":"JAMA Oncol"},{"key":"2151_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70490","volume":"8","author":"G Bushi","year":"2025","unstructured":"Bushi G, et al. Association Between GLP1 RAs and Risk of Colorectal Cancer: systematic review and meta-analysis. Health Sci Rep. 2025;8:e70490.","journal-title":"Health Sci Rep"},{"key":"2151_CR20","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"American Diabetes Association","year":"2022","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of care 2022. Diabetes Care. 2022;45:S125\u201343.","journal-title":"Diabetes Care"},{"key":"2151_CR21","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","volume":"150","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, et al. Cardiovascular, kidney, and safety outcomes with GLP-1 RAs alone and in combination with SGLT2i. Circulation. 2024;150:1781\u201390.","journal-title":"Circulation"},{"key":"2151_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2024.101594","volume":"51","author":"AJ Scheen","year":"2025","unstructured":"Scheen AJ. Cardiovascular and renal effects of GLP-1 RA and SGLT2i combination. Diabetes Metab. 2025;51:101594.","journal-title":"Diabetes Metab"},{"key":"2151_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo EM, Neuen BL, et al. Efficacy and safety of SGLT2i with and without GLP-1 RA: SMART-C meta-analysis. Lancet Diabetes Endocrinol. 2024;12:545\u201357.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2151_CR24","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hernan","year":"2022","unstructured":"Hernan MA, Wang W, Leaf DE. Target trial emulation: a framework for causal inference. JAMA. 2022;328:2446\u20137.","journal-title":"JAMA"},{"key":"2151_CR25","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1056\/NEJMp2407586","volume":"391","author":"RA Hubbard","year":"2024","unstructured":"Hubbard RA, et al. Target trial emulation for observational studies. N Engl J Med. 2024;391:1975\u20137.","journal-title":"N Engl J Med"},{"key":"2151_CR26","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","volume":"34","author":"EL Fu","year":"2023","unstructured":"Fu EL. Target trial emulation to improve causal inference. J Am Soc Nephrol. 2023;34:1305\u201314.","journal-title":"J Am Soc Nephrol"},{"key":"2151_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-086595","volume":"14","author":"N Simon-Tillaux","year":"2024","unstructured":"Simon-Tillaux N, et al. Observational analyses with the target trial emulation approach: systematic review. BMJ Open. 2024;14:e086595.","journal-title":"BMJ Open"},{"key":"2151_CR28","doi-asserted-by":"crossref","unstructured":"Palchuk MB, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6.","DOI":"10.1093\/jamiaopen\/ooad035"},{"key":"2151_CR29","doi-asserted-by":"publisher","first-page":"1516126","DOI":"10.3389\/fphar.2025.1516126","volume":"16","author":"RJ Ludwig","year":"2025","unstructured":"Ludwig RJ, et al. Methodologies and applications of TriNetX. Front Pharmacol. 2025;16:1516126.","journal-title":"Front Pharmacol"},{"key":"2151_CR30","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","volume":"158","author":"WA Ray","year":"2003","unstructured":"Ray WA. Evaluating medication effects outside clinical trials: new-user designs. Am J Epidemiol. 2003;158:915\u201320.","journal-title":"Am J Epidemiol"},{"key":"2151_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2026.113158","volume":"234","author":"YA Ateiwi","year":"2026","unstructured":"Ateiwi YA, Mahmood R, Wong HJ, Low CE, Yau CE, Lee ARYB, et al. Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026;234:113158.","journal-title":"Diabetes Res Clin Pract"},{"key":"2151_CR32","doi-asserted-by":"crossref","unstructured":"Papadopoli D, et al. mTOR as a central regulator of lifespan and aging. F1000Res. 2019;8:F1000 Faculty Rev-998.","DOI":"10.12688\/f1000research.17196.1"},{"key":"2151_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2151_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","volume":"13","author":"A Lin","year":"2025","unstructured":"Lin A, et al. GLP-1 receptor agonists and cancer risk: mechanistic understanding and clinical evidence. Biomark Res. 2025;13:50.","journal-title":"Biomark Res"},{"key":"2151_CR35","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","volume":"11","author":"H Dai","year":"2025","unstructured":"Dai H, et al. GLP-1 receptor agonists and cancer risk in adults with obesity. JAMA Oncol. 2025;11:1186\u201393.","journal-title":"JAMA Oncol"},{"key":"2151_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02151-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02151-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02151-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:06:01Z","timestamp":1781643961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-026-02151-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02151-x","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Institutional Review Board of Tri-Service General Hospital (TSGHIRB No. E202516013). The study utilized de-identified patient data from the TriNetX Global Collaborative Network, a federated research network providing access to electronic health records from healthcare organizations. The TriNetX platform is compliant with the Health Insurance Portability and Accountability Act (HIPAA) and provides only aggregated counts and statistical summaries, ensuring patient privacy and confidentiality. Due to the retrospective nature of the study and the use of de-identified data, the requirement for informed consent from individual patients was waived by the IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form (including individual details, images, or videos). All data presented are aggregate results from de-identified patient populations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work the author(s) used Claude by Anthropic in order to\u202frefine language and formatting. After using this tool, the authors reviewed and\u202fedited the content as needed and take full responsibility for the\u202fcontent of the\u202fpublication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of AI and AI-assisted technologies in the writing process"}}],"article-number":"109"}}